Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors
Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors
复制标题
DOI：
10.1038/nm.2435
复制
发表时间：
2011-10-01
期刊：
影响因子：
82.9
通讯作者：
Blanchard, Catherine
中科院分区：
文献类型：
--
作者：
Benedetti, Fabrizio;Amanzio, Martina;Blanchard, Catherine
安慰剂镇痛是由阿片类和非阿片类机制介导的，但到目前为止，对非阿片类成分一无所知。在这里，我们发现特异性CB 1大麻素受体拮抗剂5-（4-氯苯基）-1-（2，4-二氯-苯基）-4-甲基-N-（哌啶-1-基）-1H-1-吡唑-3-甲酰胺（利莫那班或SR 141716）阻断非阿片类安慰剂镇痛反应，但对阿片类安慰剂反应没有影响。这些研究结果表明，内源性大麻素系统在安慰剂镇痛在某些情况下，当阿片系统不参与的关键作用。
Placebo analgesia is mediated by both opioid and nonopioid mechanisms, but so far nothing is known about the nonopioid component. Here we show that the specific CB1 cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-1-pyrazole-3-carboxamide (rimonabant or SR141716) blocks nonopioid placebo analgesic responses but has no effect on opioid placebo responses. These findings suggest that the endocannabinoid system has a pivotal role in placebo analgesia in some circumstances when the opioid system is not involved.